8-K ·Filed Apr 22, 2026

NEU

NEWMARKET CORP
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001282637-26-000008
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Monitor upcoming quarters for stabilization in petroleum additives shipments and specialty materials product mix; the decline in profitability despite stock buybacks suggests underlying operational challenges.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
NEU ▲ +14.17% at T+60d
SHORT call ✗ call lost -14.17% · α vs SPY -9.15% · entry $683.04 → $779.81
Entry anchored
Apr 22, 03:59 PM ET
via exchange tick
T+1d
+2.03%
call -2.03% · α -1.24%
$696.88
settled 5mo ago
T+5d
-2.09%
call +2.09% · α +3.57%
$668.77
settled 5mo ago
T+20d
+3.70%
call -3.70% · α +0.93%
$708.32
settled 5mo ago
T+60d
+14.17%
call -14.17% · α -9.15%
$779.81
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

NewMarket Corporation reported Q1 2026 net income of $118.1 million ($12.62/share), down from $125.9 million ($13.26/share) in Q1 2025, driven by a 7% decline in petroleum additives shipments and a shift in specialty materials product mix. The company repurchased $125.6 million in stock.

Key Financial Metrics

EPS
$12.62
Revenue
$669.7M
-4.5% YoY
Rating
miss
Gross Margin
32.99%

Key Facts

  • Q1 2026 EPS was $12.62, down from $13.26 in Q1 2025 (7.6% decline)
  • Petroleum additives operating profit fell to $135.0 million from $142.1 million YoY due to 7% lower shipments
  • Specialty materials operating profit declined to $12.4 million from $23.2 million YoY due to product mix shift at AMPAC
  • Company repurchased $125.6 million in common stock during the quarter

Financial Impact

Net income decreased by $7.8 million year-over-year

net incomeepsoperating profitdilution

Risk Factors

  • Continued softness in petroleum additives market
  • Volatility in specialty materials segment due to product mix shifts

Market Snapshot

Exchange
NYSE
Sector
Industrial Organic Chemicals

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001282637-26-000008
Document: neu-20260422.htm0001282637-26-000008
Document: 0001282637-26-000008-index-headers.html0001282637-26-000008
Document: 0001282637-26-000008-index.html0001282637-26-000008
Document: 0001282637-26-000008.txt0001282637-26-000008
8-K Data (Synthetic)0001282637-26-000008
3 reports for NEU
Performance horizon
Filters
Rows
Reports for NEU — sortable, filterable
TypeNow
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 2/10
$961.92 $880.52▼ −8.46%▼ −6.47%$927.95 (−3.53%)
Apr 22, 2026
23w ago
8-K
BEARISH ★ 6/10
$683.04 $708.32▼ −3.70%▲ +0.93%$927.95 (−35.86%)
Mar 12, 2026
29w ago
DEFA14A
NEUTRAL ★ 3/10
$585.06 $628.74▲ +7.47%▲ +5.49%$927.95 (+58.61%)
Showing 3 of 3

US Market Status

Market Open — Closes in 3h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access